OBJECTIVE: We examined the relationship between height and prostate cancer grade. METHODS: The Early Stage Prostate Cancer Cohort Study is an observational cohort of 1,037 men diagnosed with early-stage prostate cancer, T(0-3)N(x)M(0). High-grade prostate cancer was defined as a biopsy Gleason score ≥ 7 (4 + 3). Logistic regression models were created to calculate odds ratios (OR) and 95% confidence intervals (CI) for the cross-sectional relationship between height and prostate cancer grade in the overall cohort and subpopulations. RESULTS: We identified 939 participants with a biopsy Gleason score. High-grade prostate cancer was diagnosed in 138 participants. Overall, participants in the highest quartile of height were more than twice as likely to have a Gleason score ≥ 7 (4 + 3) than participants in the lowest quartile of height, OR 2.14 (95% CI 1.11, 4.14), after multivariate adjustment. Participants in the highest quartile of height were more likely to be diagnosed with high-grade prostate cancer than participants in the lowest quartile of height among participants who were black, OR 8.00 (95% CI 1.99, 32.18), and participants who had diabetes mellitus, OR 5.09 (95% CI 1.30, 19.98). CONCLUSIONS: Height is associated with increased risk of high-grade prostate cancer overall and perhaps among certain subpopulations.
OBJECTIVE: We examined the relationship between height and prostate cancer grade. METHODS: The Early Stage Prostate Cancer Cohort Study is an observational cohort of 1,037 men diagnosed with early-stage prostate cancer, T(0-3)N(x)M(0). High-grade prostate cancer was defined as a biopsy Gleason score ≥ 7 (4 + 3). Logistic regression models were created to calculate odds ratios (OR) and 95% confidence intervals (CI) for the cross-sectional relationship between height and prostate cancer grade in the overall cohort and subpopulations. RESULTS: We identified 939 participants with a biopsy Gleason score. High-grade prostate cancer was diagnosed in 138 participants. Overall, participants in the highest quartile of height were more than twice as likely to have a Gleason score ≥ 7 (4 + 3) than participants in the lowest quartile of height, OR 2.14 (95% CI 1.11, 4.14), after multivariate adjustment. Participants in the highest quartile of height were more likely to be diagnosed with high-grade prostate cancer than participants in the lowest quartile of height among participants who were black, OR 8.00 (95% CI 1.99, 32.18), and participants who had diabetes mellitus, OR 5.09 (95% CI 1.30, 19.98). CONCLUSIONS: Height is associated with increased risk of high-grade prostate cancer overall and perhaps among certain subpopulations.
Authors: Leonard W D'Avolio; Thien M Nguyen; Wildon R Farwell; Yongming Chen; Felicia Fitzmeyer; Owen M Harris; Louis D Fiore Journal: J Am Med Inform Assoc Date: 2010 Jul-Aug Impact factor: 4.497
Authors: Susan M Gapstur; Peter Kopp; Brian C-H Chiu; Peter H Gann; Laura A Colangelo; Kiang Liu Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-12 Impact factor: 4.254
Authors: A H Heald; J K Cruickshank; L K Riste; J E Cade; S Anderson; A Greenhalgh; J Sampayo; W Taylor; W Fraser; A White; J M Gibson Journal: Diabetologia Date: 2001-03 Impact factor: 10.122
Authors: Honglei Chen; Barry A Miller; Edward Giovannucci; Richard B Hayes Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-03 Impact factor: 4.254
Authors: Jocelyn S Kasper; Yan Liu; Michael N Pollak; Nader Rifai; Edward Giovannucci Journal: Cancer Causes Control Date: 2008-03-14 Impact factor: 2.506
Authors: Young Bok Lee; Ji Hyun Lee; Yeong Ho Kim; Ji Min Seo; Dong Soo Yu; Yong Gyu Park; Kyung Do Han Journal: Sci Rep Date: 2021-10-05 Impact factor: 4.379
Authors: Artitaya Lophatananon; Sarah Stewart-Brown; Zsofia Kote-Jarai; Ali Amin Al Olama; Sara Benlloch Garcia; David E Neal; Freddie C Hamdy; Jenny L Donovan; Graham G Giles; Liesel M Fitzgerald; Melissa C Southey; Paul Pharoah; Nora Pashayan; Henrik Gronberg; Fredrik Wiklund; Markus Aly; Janet L Stanford; Hermann Brenner; Aida K Dieffenbach; Volker Arndt; Jong Y Park; Hui-Yi Lin; Thomas Sellers; Chavdar Slavov; Radka Kaneva; Vanio Mitev; Jyotsna Batra; Amanda Spurdle; Judith A Clements; Douglas Easton; Rosalind A Eeles; Kenneth Muir Journal: Br J Cancer Date: 2017-08-01 Impact factor: 7.640